Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bachem Holding AG ( (CH:BANB) ) has shared an announcement.
Bachem Holding AG has announced the appointment of Anne-Kathrin Stoller as the new CEO, effective January 1, 2026. Stoller, who has been with the company since 2006 and previously led Bachem Americas, succeeds Thomas Meier, who has significantly contributed to the company’s growth and innovation in the pharmaceutical industry. This leadership change is expected to continue Bachem’s successful trajectory as a globally leading developer and manufacturer of peptides and oligonucleotides.
The most recent analyst rating on (CH:BANB) stock is a Hold with a CHF61.00 price target. To see the full list of analyst forecasts on Bachem Holding AG stock, see the CH:BANB Stock Forecast page.
More about Bachem Holding AG
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. It provides pharmaceutical and biotech companies worldwide with products for research, clinical development, and commercial application. With headquarters in Switzerland and locations in Europe, the USA, and Asia, Bachem operates internationally and has more than 50 years of experience and industry-wide unique expertise.
Average Trading Volume: 95,764
Technical Sentiment Signal: Sell
Current Market Cap: CHF4.41B
See more data about BANB stock on TipRanks’ Stock Analysis page.